The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer.
Giovanni RossiAngela AlamaCarlo GenovaErika RijavecMarco TagliamentoFederica BielloSimona CocoMaria Giovanna Dal BelloSimona BoccardoFrancesco GrossiPublished in: Expert opinion on pharmacotherapy (2018)
Non-small cell lung cancer (NSCLC) remains one of the big cancer killers, despite the introduction of a number of approved therapeutics in recent times. Pemetrexed is a multi-target folate inhibitor, which is currently available to patients affected by advanced non-squamous NSCLC in combination with a platinum derivate in first-line therapy and as a single agent in second-line therapy. Areas covered: This review covers presents the use pemetrexed in the management of NSCLC by exploring the data available from clinical trials and meta-analyses. Data from a phase III trial confirmed its role in the first-line setting in combination with immune checkpoint inhibitors (ICIs). Furthermore, data suggested a role for pemetrexed in local and advanced NSCLC. Expert opinion: To date, in spite of the introduction of novel anti-neoplastic agents, pemetrexed still represents a cornerstone in the management of non-squamous NSCLC. Furthermore, recently published data support its role in innovative combinations including together with chemotherapy and immunotherapy.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- phase iii
- clinical trial
- big data
- brain metastases
- electronic health record
- epidermal growth factor receptor
- open label
- phase ii
- meta analyses
- end stage renal disease
- systematic review
- ejection fraction
- randomized controlled trial
- stem cells
- small molecule
- study protocol
- low grade
- artificial intelligence
- peritoneal dialysis
- combination therapy
- radiation therapy
- placebo controlled
- young adults
- clinical practice
- locally advanced
- deep learning
- data analysis
- squamous cell
- replacement therapy